Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$180.31 - $329.33
Previous CloseN/A
Volume86.50K
Average Volume (3M)619.30K
Market Cap
$21.80B
Enterprise Value$22.49B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)93.9
Beta1.11
Next Earnings
Oct 30, 2025EPS Estimate
1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding70,392,530
10 Day Avg. Volume854,963
30 Day Avg. Volume619,303
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue10.23
Enterprise Value/Gross Profit14.53
Enterprise Value/Ebitda53.77
Forecast
1Y Price Target
$359.44Price Target Upside13.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Financial PerformancePODD reported a +6% sales beat driven by strong execution both in the US and OUS, with raised FY25 guidance implying ~MSD % upside to 2H25 consensus.
Growth ProspectsInsulet is considered one of the best-positioned companies in the diabetes MedTech sector, with favorable growth catalysts like strong international momentum and increasing profitability.
Market StrategyInsulet had its highest quarter of competitive switches, indicating a successful strategy in attracting customers from competitors.
Bears Say
Investor ConcernsInvestors are still concerned about longer-term adjusted OMs as management would not commit to continued expansion.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $180.31 and its highest was $329.33 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $21.80B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 30, 2025 which is in 75 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 07, 2025. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.14.
How many shares outstanding does Insulet have?
Insulet has 70,392,530 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.17 in its last earnings report, beating expectations of $0.92. Following the earnings report the stock price went up 1.169%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$359.44 (13.83% Upside)
$359.44 (13.83% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 188.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.63%
12-Months-Change
Fundamentals
Return on Equity
19.18%
Trailing 12-Months
Asset Growth
20.39%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation is a medical device company that specializes in the development and manufacturing of innovative insulin delivery systems, primarily for people with diabetes. The company is best known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump designed to improve the quality of life for individuals managing diabetes. Insulet operates in the healthcare sector, focusing on diabetes management and has expanded its product offerings to include advanced technology that integrates with continuous glucose monitoring systems.
PODD Company Deck
PODD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, highlighted by significant revenue growth, expansion in international markets, and an increase in the prescriber base. The company also raised its full-year guidance, reflecting strong performance and confidence in future growth. However, there were some financial challenges, such as inventory-related charges and increased interest expenses. Overall, positive aspects significantly outweighed the negatives.View all PODD earnings summariesPODD Revenue Breakdown
74.73% U.S.
25.27% International
PODD Stock 12 Month Forecast
Average Price Target
$359.44
▲(13.83% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
42.19% Mutual Funds
24.78% Other Institutional Investors
6.14% Public Companies and Individual Investors